Actelion Pharmaceuticals Ltd: Actelion's Annual General Meeting of Shareholders held in Basel, Switzerland - All Board proposals

      Actelion Pharmaceuticals Ltd: Actelion's Annual General Meeting of     Shareholders held in Basel, Switzerland - All Board proposals approved  Actelion Pharmaceuticals Ltd / Actelion's Annual General Meeting of Shareholders held in Basel, Switzerland - All Board proposals approved . Processed and transmitted by NASDAQ OMX Corporate Solutions. The issuer is solely responsible for the content of this announcement.  ALLSCHWIL/BASEL, SWITZERLAND - 08 May 2014 - At today's Annual General Meeting (AGM) of Actelion Ltd  (SIX: ATLN), held  in Basel, Switzerland,  shareholders  voted in favor of all proposals by  the Board of Directors with a  significant  majority.  The meeting was attended by 220 shareholders. A total of 62'836'116 shares  or  52.25% of the total outstanding shares were represented.  Led by the Chairman of the Board, Jean-Pierre Garnier, the company presented a review of  the  2013 performance.  Highlights  included the  strong  financial  results, approval  and  subsequent  successful  launch  of  its  new  medicine  Opsumit^®,  continued  demand  for  key  products  Tracleer^®  and  Veletri^®,  strengthening of its specialty franchise through the acquisition of US company Ceptaris, and  considerable progress  in  clinical development.  The  chairman  reminded the shareholders that Actelion  once again created substantial  value  in 2013, with a total shareholder return of 76%.  The shareholders approved the Business Report consisting of the Annual Report, the Annual Statutory Accounts and the Consolidated Accounts for the year 2013.  A proposal  by  the  Board  to appropriate  available  earnings  from  capital  contribution and  distribute as  a dividend  in  the amount  of CHF  1.20  per  registered share was passed by shareholders.  The ex-dividend date will be  12  May 2014 and the payment will be made on 15 May 2014.  Shareholders endorsed  the 2013  compensation report  by way  of  consultative  vote.  The shareholders granted discharge  to all members of  the Board of  Directors  and of the Senior Management.  A proposal by the Board to reduce share capital by cancellation of repurchased shares was approved by the shareholders.  Actelion's shareholders re-elected all  members of the  Board which stood  for  election for  a term  of  office until  the conclusion  of  the 2015  AGM.  In  addition, the shareholders elected Mr.  Jean-Pierre Garnier as Chairperson  of  the Board and Werner Henrich, Jean-Pierre  Garnier and John J. Greisch to  the  Compensation Committee.  Mr. Armin Kessler did not stand for re-election at the 2014 AGM. Commenting on his long service,  Jean-Pierre Garnier,  Chairman of the  Board of  Directors,  said: "Armin Kessler has served as  an integral member of Actelion's Board  of  Directors for 10 years.  During this time his  in-depth and vast knowledge  of  the pharmaceutical  industry  as well  as  his mentoring  skills  have  helped  Actelion to become  the successful global  player it is  today. He has  served  Actelion's shareholders well and we thank him for his dedicated service."  Following the AGM, the Board of Directors of Actelion comprises a total of  10  members: Jean-Pierre  Garnier (Chairman),  Juhani Anttila,  Robert  Bertolini,  Jean-Paul Clozel, Carl Feldbaum, John J. Greisch, Peter Gruss, Werner Henrich, Michael Jacobi, and Jean Malo.  BDO AG, represented by  Mr. Marc Schaffner, was  elected as Independent  Proxy  for a term of office until the conclusion of the 2015 AGM.  Ernst &  Young was  re-elected as  the Company's  statutory auditors  for  the  business year 2014.  Shareholders  also  approved  the  proposed  revisions  to  the  Articles   of  Association, including  the modifications  which  ensure compliance  with  the  Federal Council's Ordinance in relation to the "Minder initiative".  Specifically, shareholders agreed to the principles proposed by the Board with regards to the remuneration of the members  of the Board of Directors and  the  Core Executive Committee. As a result, shareholders will be asked to vote on a combination of binding and advisory votes at the 2015 AGM as follows:    *Binding approval of the maximum aggregate amount of the compensation for     the Board of Directors for the period until the 2016 AGM;   *Binding approval of the aggregate compensation amount for the Core     Executive Committee for 2016; and   *A non-binding consultative vote on the company's annual compensation     report 2014, in which the amounts of the compensation received by the     Board of Directors and the Core Executive Committee, as well as further     details regarding the remuneration structure, will be disclosed.                                           ###    NOTES TO THE EDITOR  ABOUT ACTELION LTD.  Actelion Ltd. is a leading biopharmaceutical company focused on the discovery, development and  commercialization  of  innovative  drugs  for  diseases  with  significant unmet medical needs.  Actelion is a leader  in the field of  pulmonary arterial hypertension  (PAH).  Our portfolio  of PAH  treatments covers  the spectrum  of disease,  from  WHO  Functional Class (FC) II through to FC IV, with oral, inhaled and  intravenous  medications. Although not available in all countries, Actelion has  treatments  approved by health authorities for  a number of specialist diseases  including  Type 1  Gaucher  disease,  Niemann-Pick  type C  disease,  Digital  Ulcers  in  patients suffering from systemic sclerosis, and mycosis fungoides in  patients  with cutaneous T-cell lymphoma.  Founded in late 1997, with now over 2,400 dedicated professionals covering all key markets  around the  world  including the  US,  Japan, China,  Russia  and  Mexico,  Actelion  has  its  corporate  headquarters  in  Allschwil  /  Basel,  Switzerland.  Actelion shares are traded on the SIX Swiss Exchange (ticker symbol: ATLN)  as  part of  the  Swiss  blue-chip  index  SMI  (Swiss  Market  Index  SMI®).  All  trademarks are legally protected.    For further information please contact:  Andrew Jones Director, Corporate Communications Actelion Pharmaceuticals Ltd, Gewerbestrasse 16, CH-4123 Allschwil +41 61 565 62 62    Press Release PDF  ------------------------------------------------------------------------------  This announcement is distributed by NASDAQ OMX Corporate Solutions on behalf of NASDAQ OMX Corporate Solutions clients. The issuer of this announcement warrants that they are solely responsible for the content, accuracy and originality of the information contained therein. Source: Actelion Pharmaceuticals Ltd via Globenewswire HUG#1783819  --- End of Message ---  Actelion Pharmaceuticals Ltd Gewerbestrasse 16 Allschwil Switzerland  ISIN: CH0010532478;  
Press spacebar to pause and continue. Press esc to stop.